Usefulness of endoscopic evaluation with fluorescence after endovesical BCG in the management of non-invasive bladder tumors

被引:3
作者
Charbit, D. [1 ]
Arnoux, V. [2 ]
Gobet, F. [3 ]
Pasquier, D. [4 ]
Descotes, J. -L. [2 ]
Pfister, C. [1 ]
机构
[1] CHU Rouen, Hop Charles Nicolle, Serv Urol, F-76031 Rouen, France
[2] CHU Grenoble, Serv Urol, F-38043 Grenoble 9, France
[3] CHU Rouen, Serv Anatomopathol, F-76031 Rouen, France
[4] CHU Grenoble, Serv Anatomopathol, F-38043 Grenoble 9, France
来源
PROGRES EN UROLOGIE | 2014年 / 24卷 / 09期
关键词
Non-invasive bladder tumors; BCG-theimpy; Flbbrescence; WHITE-LIGHT CYSTOSCOPY; CARCINOMA IN-SITU; PHASE-III; CANCER; RECURRENCE; PROGRESSION;
D O I
10.1016/j.purol.2014.01.001
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction. - The objective of this retrospective study was to assess the usefulness of fluorescence during cystoscopy after BCG-therapy in the management of non-invasive bladder tumors. Patients and methods. - Fifty-four patients were enrolled: Ta (15 cases), T1 (27 cases) carcinoma in situ (CIS) atone (12 cases) or associated (14 cases). Urine cytology was of high grade and a second look was systematically performed in case of lamina propria infiltration. Initial therapy with 6 intravesical BCG instillations (81 mg) was performed with histologic and endoscopic bladder evaluation 3 months after initial resection using hexylaminolevulinate fluorescence (Hexvix (R) 85 mg). Results. - Urine cytology was negative in 27 cases, suspicious in 12 cases and positive in 15 cases. With standard endoscopy under white light, mucosal bladder was normal in 32 cases, the use of fluorescence detected 8 tumour lesions confirmed with histology (CIS). When mucosal bladder was suspect under white light (22 patients), fluorescence was positive in 16 cases with 10 matching histological analysis (CIS and/or residual tumoral lesion). Therefore, despite high false positive rate with persistent mucosal bladder inflammation (38%), fluorescence guided endoscopy has allowed the diagnosis of suspect lesions not detected with white light with negative urine cytology. Conclusion. - Hexvix (R) fluorescence after intravesical BCG instillations may improve persistent carcinoma in situ detection when performed 3 months after induction treatment. However, a multicenter prospective study will be necessary in future to confirm these preliminary results. (C) 2014 Published by Elsevier Masson SAS.
引用
收藏
页码:551 / 555
页数:5
相关论文
共 17 条
  • [11] Ray ER, 2009, BJIU, V105, P789
  • [12] Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy
    Schmidbauer, J
    Witjes, F
    Schmeller, N
    Donat, R
    Susani, M
    Marberger, M
    [J]. JOURNAL OF UROLOGY, 2004, 171 (01) : 135 - 138
  • [13] The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer
    Solsona, E
    Iborra, I
    Dumont, R
    Rubio-Briones, J
    Casanova, J
    Almenar, S
    [J]. JOURNAL OF UROLOGY, 2000, 164 (03) : 685 - 689
  • [14] Stenzl A, 2011, CANCER-AM CANCER SOC, V117, P938, DOI [10.1002/cncr.25523, 10.1590/S1677-55382011000500027]
  • [15] Hexaminolevulinate Guided Fluorescence Cystoscopy Reduces Recurrence in Patients With Nonmuscle Invasive Bladder Cancer
    Stenzl, Arnulf
    Burger, Maximilian
    Fradet, Yves
    Mynderse, Lance A.
    Soloway, Mark S.
    Witjes, J. Alfred
    Kriegmair, Martin
    Karl, Alexander
    Shen, Yu
    Grossman, H. Barton
    [J]. JOURNAL OF UROLOGY, 2010, 184 (05) : 1907 - 1913
  • [16] Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials
    Sylvester, RJ
    van der Meijden, APM
    Oosterlinck, W
    Witjes, JA
    Bouffioux, C
    Denis, L
    Newling, DWW
    Kurth, K
    [J]. EUROPEAN UROLOGY, 2006, 49 (03) : 466 - 477
  • [17] Interest and terms of using fluorescence-guided cystoscopy in 2011 for bladder cancer management: Review of the French Urological Oncology Committee
    Wallerand, H.
    Roupret, M.
    Lure, S.
    Houede, N.
    Neuzillet, Y.
    Comperat, E.
    Quintens, H.
    Pignot, G.
    Roy, C.
    Soulie, M.
    Pfister, C.
    [J]. PROGRES EN UROLOGIE, 2011, 21 (12): : 823 - 828